Integra LifeSciences Holdings Corporation

NASDAQ:IART

Medical - Devices

Healthcare
$13.86 +4.71%

+$0.81 today

Market cap
$1.08B
Beta
1.25
P/E (TTM)
-2.8
EPS (TTM)
-$6.44
52W Low $8.70High $18.26

Volume 0.58M

Average 0.96M

IART Interest Expense

Cost of servicing the company's debt during the period.

Integra LifeSciences Holdings CorporationNASDAQ: IART

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense growth accelerates

Q1 FY2026 interest expense of $26.85M rose 32.6% year over year, ahead of the +22.1% change in trailing-twelve-month interest expense. Sequentially, it rose 13.4% from the prior quarter. Over 3 fiscal years it compounded at +20.3% a year.

Context

  • Interest expense amounted to 5.3% of revenue in FY2025, up 0.9 pp from a year earlier.
  • Interest expense increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +32.6% holds above the trailing-twelve-month pace of +22.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$26.85M+13.4% QoQ
Last fiscal yearDec 2025
$86.26M+22.1% YoY
LTMMar 2026
$94.29M+22.1% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+32.6%——
1 year+22.1%——
3-year CAGR+20.3%——
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
86.26M USD
Year-over-year change
+22.1%
4-year CAGR
+14.4%

Interest Expense vs competitors

How IART compares with its peers on the latest reported figures

  • IART's LTM Mar 2026 interest expense of $94.29M is the 3rd highest of the 11 companies compared; the peer median is $21.47M.
  • Its year-over-year change of +22.1% is the 3rd highest of 11, against a peer median of -27.5%.
  • Interest expense amounts to 5.7% of revenue for IART, versus a peer median of 2.5%.
IART Competitors Peer median
Interest Expense for IART and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SYKStryker CorporationLTM Jun 2026$827M +420.1%+21.7%3.2%
SNNSmith & Nephew plcFY2025$141.33M -5.8%+20.9%2.3%
IARTIntegra LifeSciences Holdings CorporationLTM Mar 2026$94.29M +22.1%+20.3%5.7%
ATECAlphatec Holdings, Inc.LTM Mar 2026$42.09M +53.7%+56.6%5.3%
CNMDCONMED CorporationLTM Mar 2026$29.86M -17.0%+2.5%2.2%
AORTArtivion, Inc.LTM Mar 2026$24.29M -28.8%+13.4%5.3%
OFIXOrthofix Medical Inc.LTM Mar 2026$18.65M -37.0%+138.6%2.3%
XTNTXtant Medical Holdings, Inc.LTM Mar 2026$3.23M -26.2%+29.5%2.6%
TELATELA Bio, Inc.LTM Jun 2026$2.86M -43.2%+9.0%3.6%
AXGNAxoGen, Inc.LTM Sep 2026$2.41M -85.1%+131.1%0.9%
GMEDGlobus Medical, Inc.LTM Jun 2026$0 -100.0%—0.0%
Peer median (excluding IART) $21.47M-27.5%+21.7%2.5%

Competitors are the stored peer set for IART. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.54B1.56B1.54B1.61B1.64B
Cost of Revenue597.81M587.36M656.84M728.47M790.01M
Gross Profit944.64M970.31M884.74M882.06M845.23M
Gross Margin61.2%62.3%57.4%54.8%51.7%
Research & Development93.05M101.19M104.19M115.38M98.97M
Selling, General & Admin637.45M616.32M656.64M716.98M699.7M
Operating Expenses747.41M731.39M773.21M853.65M776.92M
Depreciation & Amortization123.67M121.12M123.51M140.5M151.05M
EBITDA366.33M384.6M255.96M193.29M(326.2M)
EBITDA Margin23.7%24.7%16.6%12.0%-19.9%
Operating Income197.23M238.92M111.53M28.41M68.32M
Operating Margin12.8%15.3%7.2%1.8%4.2%
Interest Income6.74M11.92M17.2M20.04M18.47M
Interest Expense50.4M49.59M51.38M70.63M86.26M
Other Income / Expenses17.45M(25.03M)(30.46M)(46.65M)(631.82M)
Income Before Tax214.68M213.89M81.07M(18.24M)(563.5M)
Pre-Tax Margin13.9%13.7%5.3%-1.1%-34.5%
Income Tax Expense45.6M33.34M13.33M(11.29M)(47.03M)
Net Income169.08M180.55M67.74M(6.94M)(516.47M)
Net Margin11.0%11.6%4.4%-0.4%-31.6%
EPS (Basic)2.002.180.87(0.09)(6.73)
EPS (Diluted)1.982.160.84(0.09)(6.73)
Weighted Avg Shares84.7M83M78.17M77.01M76.75M
Weighted Avg Shares (Diluted)85.49M83.52M80.34M77.01M76.75M

Integra LifeSciences Holdings Corporation

NASDAQ:IART

Intrinsic Alpha fair value

Locked

Current Price

$13.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.